← Back to Clinical Trials
Recruiting NCT07094906

NCT07094906 Handgrip Exercise Training and CKD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07094906
Status Recruiting
Phase
Sponsor Emory University
Condition Chronic Kidney Diseases
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-04
Primary Completion 2027-12

Trial Parameters

Condition Chronic Kidney Diseases
Sponsor Emory University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 45 Years
Max Age 85 Years
Start Date 2026-04
Completion 2027-12
Interventions
Isometric handgrip exercise trainingSham Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to find out if regular handgrip exercise performed at home can improve blood pressure at rest and during exercise in patients with chronic kidney disease (CKD). This study is also intended to understand what causes an increase in blood pressure at rest and during exercise (i.e., increased adrenaline levels, or decreased ability of blood vessels to dilate). Patients with CKD will be recruited from primary care, Nephrology and other subspecialty Clinics throughout the Emory Healthcare System. Participants will attend 4 visits of 2-3 hours and 3 visits of 1-2 hours. The home exercise training will last for 8 weeks.

Eligibility Criteria

Inclusion Criteria: * Patients with CKD (Stages IIIa and IV), * Ages 45-85 years who do not regularly exercise (defined as exercising less than 20 minutes twice per week), willing and able to cooperate with the protocol. * CKD Stages III and IV will be defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified CKD-EPI equations. * Patients with CKD must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months). Exclusion Criteria: * Severe CKD (eGFR\<15 cc/minute) * Metabolic alkalosis (serum bicarbonate \> 28 meq/L) * Ongoing drug or alcohol abuse * Diabetic neuropathy * Any serious systemic disease that might influence survival * Severe anemia with hgb level \<10 g/dL * Clinical evidence of congestive heart failure or ejection fraction below 35%, symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history, treatment with central alpha agonists (clonidine) * Un

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology